Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups

Research output: Contribution to journalReview article

Abstract

Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including immune homeostasis and polymorphisms in the major and minor histocompatibility molecules, cytokines, and chemokines. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell biologic process, whose deviations from normality determine the rules of engagement with the host's response, the Society for Immunotherapy of Cancer (SITC) convened a task force of experts from various disciplines including, immunology, oncology, biophysics, structural biology, molecular and cellular biology, genetics, and bioinformatics to address the complexity of CIR from a holistic view. The task force was launched by a workshop held in San Francisco on May 14-15, 2018 aimed at two preeminent goals: 1) to identify the fundamental questions related to CIR and 2) to create an interactive community of experts that could guide scientific and research priorities by forming a logical progression supported by multiple perspectives to uncover mechanisms of CIR. This workshop was a first step toward a second meeting where the focus would be to address the actionability of some of the questions identified by working groups. In this event, five working groups aimed at defining a path to test hypotheses according to their relevance to human cancer and identifying experimental models closest to human biology, which include: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional contributions to CIR, 4) Determinant(s) of Immunogenic Cell Death that modulate CIR, and 5) Experimental Models that best represent CIR and its conversion to an immune responsive state. This manuscript summarizes the contributions from each group and should be considered as a first milestone in the path toward a more contemporary understanding of CIR. We appreciate that this effort is far from comprehensive and that other relevant aspects related to CIR such as the microbiome, the individual's recombined T cell and B cell receptors, and the metabolic status of cancer and immune cells were not fully included. These and other important factors will be included in future activities of the taskforce. The taskforce will focus on prioritization and specific actionable approach to answer the identified questions and implementing the collaborations in the follow-up workshop, which will be held in Houston on September 4-5, 2019.

Original languageEnglish
Pages (from-to)131
JournalJournal for ImmunoTherapy of Cancer
Volume7
Issue number1
DOIs
Publication statusPublished - May 22 2019

Fingerprint

Immunotherapy
Education
Neoplasms
Advisory Committees
Allergy and Immunology
Theoretical Models
Biophysics
Histocompatibility
San Francisco
Genomic Instability
Microbiota
Computational Biology
Chemokines

Cite this

Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups (2019). Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal for ImmunoTherapy of Cancer, 7(1), 131. https://doi.org/10.1186/s40425-019-0602-4

Toward a comprehensive view of cancer immune responsiveness : a synopsis from the SITC workshop. / Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

In: Journal for ImmunoTherapy of Cancer, Vol. 7, No. 1, 22.05.2019, p. 131.

Research output: Contribution to journalReview article

Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups 2019, 'Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop', Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, pp. 131. https://doi.org/10.1186/s40425-019-0602-4
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal for ImmunoTherapy of Cancer. 2019 May 22;7(1):131. https://doi.org/10.1186/s40425-019-0602-4
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. / Toward a comprehensive view of cancer immune responsiveness : a synopsis from the SITC workshop. In: Journal for ImmunoTherapy of Cancer. 2019 ; Vol. 7, No. 1. pp. 131.
@article{77ad54c0be57435cb80cd0512d34c3d0,
title = "Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop",
abstract = "Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including immune homeostasis and polymorphisms in the major and minor histocompatibility molecules, cytokines, and chemokines. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell biologic process, whose deviations from normality determine the rules of engagement with the host's response, the Society for Immunotherapy of Cancer (SITC) convened a task force of experts from various disciplines including, immunology, oncology, biophysics, structural biology, molecular and cellular biology, genetics, and bioinformatics to address the complexity of CIR from a holistic view. The task force was launched by a workshop held in San Francisco on May 14-15, 2018 aimed at two preeminent goals: 1) to identify the fundamental questions related to CIR and 2) to create an interactive community of experts that could guide scientific and research priorities by forming a logical progression supported by multiple perspectives to uncover mechanisms of CIR. This workshop was a first step toward a second meeting where the focus would be to address the actionability of some of the questions identified by working groups. In this event, five working groups aimed at defining a path to test hypotheses according to their relevance to human cancer and identifying experimental models closest to human biology, which include: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional contributions to CIR, 4) Determinant(s) of Immunogenic Cell Death that modulate CIR, and 5) Experimental Models that best represent CIR and its conversion to an immune responsive state. This manuscript summarizes the contributions from each group and should be considered as a first milestone in the path toward a more contemporary understanding of CIR. We appreciate that this effort is far from comprehensive and that other relevant aspects related to CIR such as the microbiome, the individual's recombined T cell and B cell receptors, and the metabolic status of cancer and immune cells were not fully included. These and other important factors will be included in future activities of the taskforce. The taskforce will focus on prioritization and specific actionable approach to answer the identified questions and implementing the collaborations in the follow-up workshop, which will be held in Houston on September 4-5, 2019.",
author = "{Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups} and Davide Bedognetti and Michele Ceccarelli and Lorenzo Galluzzi and Rongze Lu and Karolina Palucka and Josue Samayoa and Stefani Spranger and Sarah Warren and Kwok-Kin Wong and Elad Ziv and Diego Chowell and Coussens, {Lisa M} and {De Carvalho}, {Daniel D} and DeNardo, {David G} and J{\'e}r{\^o}me Galon and Kaufman, {Howard L} and Tomas Kirchhoff and Lotze, {Michael T} and Luke, {Jason J} and Minn, {Andy J} and Katerina Politi and Shultz, {Leonard D} and Richard Simon and V{\'e}steinn Th{\'o}rsson and Weidhaas, {Joanne B} and Ascierto, {Maria Libera} and Ascierto, {Paolo Antonio} and Barnes, {James M} and Valentin Barsan and Bommareddy, {Praveen K} and Adrian Bot and Church, {Sarah E} and Gennaro Ciliberto and {De Maria}, Andrea and Dobrin Draganov and Ho, {Winson S} and McGee, {Heather M} and Anne Monette and Murphy, {Joseph F} and Paola Nistic{\`o} and Wungki Park and Maulik Patel and Michael Quigley and Laszlo Radvanyi and Harry Raftopoulos and Nils-Petter Rudqvist and Alexandra Snyder and Sweis, {Randy F} and Sara Valpione and Butterfield, {Lisa H}",
year = "2019",
month = "5",
day = "22",
doi = "10.1186/s40425-019-0602-4",
language = "English",
volume = "7",
pages = "131",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Toward a comprehensive view of cancer immune responsiveness

T2 - a synopsis from the SITC workshop

AU - Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups

AU - Bedognetti, Davide

AU - Ceccarelli, Michele

AU - Galluzzi, Lorenzo

AU - Lu, Rongze

AU - Palucka, Karolina

AU - Samayoa, Josue

AU - Spranger, Stefani

AU - Warren, Sarah

AU - Wong, Kwok-Kin

AU - Ziv, Elad

AU - Chowell, Diego

AU - Coussens, Lisa M

AU - De Carvalho, Daniel D

AU - DeNardo, David G

AU - Galon, Jérôme

AU - Kaufman, Howard L

AU - Kirchhoff, Tomas

AU - Lotze, Michael T

AU - Luke, Jason J

AU - Minn, Andy J

AU - Politi, Katerina

AU - Shultz, Leonard D

AU - Simon, Richard

AU - Thórsson, Vésteinn

AU - Weidhaas, Joanne B

AU - Ascierto, Maria Libera

AU - Ascierto, Paolo Antonio

AU - Barnes, James M

AU - Barsan, Valentin

AU - Bommareddy, Praveen K

AU - Bot, Adrian

AU - Church, Sarah E

AU - Ciliberto, Gennaro

AU - De Maria, Andrea

AU - Draganov, Dobrin

AU - Ho, Winson S

AU - McGee, Heather M

AU - Monette, Anne

AU - Murphy, Joseph F

AU - Nisticò, Paola

AU - Park, Wungki

AU - Patel, Maulik

AU - Quigley, Michael

AU - Radvanyi, Laszlo

AU - Raftopoulos, Harry

AU - Rudqvist, Nils-Petter

AU - Snyder, Alexandra

AU - Sweis, Randy F

AU - Valpione, Sara

AU - Butterfield, Lisa H

PY - 2019/5/22

Y1 - 2019/5/22

N2 - Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including immune homeostasis and polymorphisms in the major and minor histocompatibility molecules, cytokines, and chemokines. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell biologic process, whose deviations from normality determine the rules of engagement with the host's response, the Society for Immunotherapy of Cancer (SITC) convened a task force of experts from various disciplines including, immunology, oncology, biophysics, structural biology, molecular and cellular biology, genetics, and bioinformatics to address the complexity of CIR from a holistic view. The task force was launched by a workshop held in San Francisco on May 14-15, 2018 aimed at two preeminent goals: 1) to identify the fundamental questions related to CIR and 2) to create an interactive community of experts that could guide scientific and research priorities by forming a logical progression supported by multiple perspectives to uncover mechanisms of CIR. This workshop was a first step toward a second meeting where the focus would be to address the actionability of some of the questions identified by working groups. In this event, five working groups aimed at defining a path to test hypotheses according to their relevance to human cancer and identifying experimental models closest to human biology, which include: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional contributions to CIR, 4) Determinant(s) of Immunogenic Cell Death that modulate CIR, and 5) Experimental Models that best represent CIR and its conversion to an immune responsive state. This manuscript summarizes the contributions from each group and should be considered as a first milestone in the path toward a more contemporary understanding of CIR. We appreciate that this effort is far from comprehensive and that other relevant aspects related to CIR such as the microbiome, the individual's recombined T cell and B cell receptors, and the metabolic status of cancer and immune cells were not fully included. These and other important factors will be included in future activities of the taskforce. The taskforce will focus on prioritization and specific actionable approach to answer the identified questions and implementing the collaborations in the follow-up workshop, which will be held in Houston on September 4-5, 2019.

AB - Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including immune homeostasis and polymorphisms in the major and minor histocompatibility molecules, cytokines, and chemokines. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell biologic process, whose deviations from normality determine the rules of engagement with the host's response, the Society for Immunotherapy of Cancer (SITC) convened a task force of experts from various disciplines including, immunology, oncology, biophysics, structural biology, molecular and cellular biology, genetics, and bioinformatics to address the complexity of CIR from a holistic view. The task force was launched by a workshop held in San Francisco on May 14-15, 2018 aimed at two preeminent goals: 1) to identify the fundamental questions related to CIR and 2) to create an interactive community of experts that could guide scientific and research priorities by forming a logical progression supported by multiple perspectives to uncover mechanisms of CIR. This workshop was a first step toward a second meeting where the focus would be to address the actionability of some of the questions identified by working groups. In this event, five working groups aimed at defining a path to test hypotheses according to their relevance to human cancer and identifying experimental models closest to human biology, which include: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional contributions to CIR, 4) Determinant(s) of Immunogenic Cell Death that modulate CIR, and 5) Experimental Models that best represent CIR and its conversion to an immune responsive state. This manuscript summarizes the contributions from each group and should be considered as a first milestone in the path toward a more contemporary understanding of CIR. We appreciate that this effort is far from comprehensive and that other relevant aspects related to CIR such as the microbiome, the individual's recombined T cell and B cell receptors, and the metabolic status of cancer and immune cells were not fully included. These and other important factors will be included in future activities of the taskforce. The taskforce will focus on prioritization and specific actionable approach to answer the identified questions and implementing the collaborations in the follow-up workshop, which will be held in Houston on September 4-5, 2019.

U2 - 10.1186/s40425-019-0602-4

DO - 10.1186/s40425-019-0602-4

M3 - Review article

C2 - 31113486

VL - 7

SP - 131

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

ER -